NY-ANTIDOTE-TECHNOLOGIES
14.4.2020 15:02:11 CEST | Business Wire | Press release
Antidote Technologies, a digital patient engagement company with strategic partnerships across the clinical development ecosystem, today announced the addition of COVID-19 trials to its signature state-of-the-art clinical trial search platform, Antidote Match™. For the first time, people can use Antidote’s search to be quickly matched to clinical trials for compounds aimed at COVID-19 treatment and prevention.
Antidote Match is the first trial matching engine that uses structured eligibility criteria (using industry standard and custom-designed ontologies) and proprietary algorithms to explore a patient’s eligibility for every trial. When searching COVID-19 trials, patients answer a handful of questions about their health, and the Antidote Match engine traverses all COVID-19 trials in ClinicalTrials.gov, regardless of location, to connect them with the right studies.
Antidote’s search is available on the Antidote website and on the websites of 250+ patient advocacy groups, where Antidote powers clinical trial search. “Antidote is a tremendous resource for families looking for clear, reliable information on clinical trials, as well as scientists hoping to accelerate the path to new and more effective treatments,” said Michael Buckley, Vice President of Public Affairs at BrightFocus Foundation.
Traditionally, medical research has been a slow process — it takes an average of ten years for a drug to go from initial discovery to pharmacy shelves.1 “Right now, the world doesn’t have ten years,” said Laurent Schockmel, CEO of Antidote. “COVID-19 research is urgent, and all avenues that speed up research should be explored. That’s why Antidote is providing this free search tool to all. It’s simple: the more patients search and enroll, the faster medical research can lead to breakthroughs to treat and prevent COVID-19.”
Clinical trials for COVID-19 cannot move forward without volunteers — both those who are sick and those who are healthy. To be part of finding a solution to COVID-19, please visit http://www.antidote.me/covid-19 .
About Antidote
Antidote is a digital health company on a mission to accelerate medical research. In a world where eighty percent of clinical trials are delayed or closed due to lack of participants, Antidote uses precision recruitment to match the right patients with the right trials.2 Antidote strikes the right balance between technology and human touch to deliver high-quality patient engagement through the integration of data-driven technologies, digital expertise, deep domain experience, a diverse partner network, and personalized patient and site services. Antidote was launched as TrialReach and is based in the US and UK. For more information, please visit www.antidote.me .
References
- PhRMA. (2015). Biopharmaceutical Research & Development: The Process Behind New Medicines [whitepaper]. http://phrma-docs.phrma.org/sites/default/files/pdf/rd_brochure_022307.pdf .
- Hargreaves, B. (2016, March). Clinical Trials and their Patients: The Rising Costs and How to Stem the Loss. Pharmafile. http://www.pharmafile.com/news/511225/clinical-trials-and-their-patients-rising-costs-and-how-stem-loss .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200414005211/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
In Line With the LEAP | 28 Portfolio Rotation Strategy, Bureau Veritas Signs an Agreement to Sell Its Oil & Petrochemicals and Coal Testing and Inspection Business30.6.2026 07:30:00 CEST | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces that it has entered exclusive negotiations with Triton Partners regarding the sale of its Oil & Petrochemicals and Coal testing and inspection business. This strategic divestment is in full alignment with the Group’s LEAP | 28 strategy. The proposed transaction would include the Oil & Petrochemicals and Coal testing and inspection activities. In 2025, this business generated approximately EUR 450 million in revenue operating a global network across multiple countries, with a significant footprint of operational sites and employees. This business grew at a lower rate than the Group and is margin dilutive. It is included within Bureau Veritas’ “Optimize value and impact” portfolio and reported under the Agri-Food & Commodities division. The transaction supports the strategic objective to increase exposure to higher growth and margin businesses. A key milestone in LEAP | 28 portfolio rotati
Corient Accelerates European Growth With the Addition of Letus Private Office30.6.2026 07:15:00 CEST | Press release
Leading French multi-family office with approximately US$5 billion in assets is Corient’s fourth European acquisition, growing firm’s global assets to approximately US$523 billion Corient today announced an agreement to acquire Letus Private Office (“Letus”), an independent multi-family office and wealth advisory firm serving entrepreneurs, founders and other ultra-high-net-worth individuals and families across France and Europe. The acquisition, subject to closing, builds on recent transactions that have made Corient the world’s largest multi-family office and non-bank wealth manager focused on ultra-high-net worth and high-net-worth clients. Paris-based Letus was founded in 2016 and is led by Managing Partners Anice Chlagou, Stephen Lasry and Alexandre Tsouli, and Partner Sacha Levy. It manages and administers approximately €4.1 billion (about US$5 billion). Letus serves ultra-high-net worth clients, primarily entrepreneurs and their families, providing comprehensive, bespoke service
“BOCCHI THE ROCK!” SeisyunComplex Premiered on June 20!30.6.2026 07:00:00 CEST | Press release
A New Work for “TOKYO Night & Light” — Surpassing 1.4 Million Total Visitors The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260625185578/en/ We are pleased to announce that the first screening of “BOCCHI THE ROCK!” SeisyunComplex, a new projection mapping work inspired by the highly popular anime “BOCCHI THE ROCK!”, was held on Saturday, June 20. Following its premiere, the work will be screened throughout the year as part of the weekday and weekend lineup of “TOKYO Night & Light”. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.4 million. As on
Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease30.6.2026 07:00:00 CEST | Press release
Hengrui Pharma, a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique EyeSol® water-free platform technology, announce today that on June 23, 2026, the China National Medical Products Administration (NMPA) has approved Heng Yi® (0.1% cyclosporine ophthalmic solution) for the treatment of patients with dry eye disease, aiming to increase tear secretion in patients with reduced tear production and improve the sign of the disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629052295/en/ Heng Yi Heng Yi® is the first and only water-free 0.1% cyclosporine ophthalmic solution and the second dry eye disease drug product approved in China based on the EyeSol® platform technology, following the approval of Heng Qin® (perfluorohexyloctane ophthalmic solution) in 202
Nebex Raises $30M Seed Round Led by GV to Build Market Infrastructure for the Global Space Economy29.6.2026 17:38:00 CEST | Press release
The new funding and banking relationship allow Nebex to scale the market and unlock the commercial space economy. Nebex, the market infrastructure platform for the global space economy, announced a $30M seed investment led by GV (Google Ventures), with participation from other top-tier venture funds. The company also announced a banking relationship with J.P. Morgan. The capital raise and new banking relationship will help Nebex scale its platform and connect sovereign space programs with the founders and companies building new technologies to serve the space industry. "We built Nebex because we've seen firsthand that ambitious space founders struggle to deliver complex sovereign programs due to the lack of capital markets infrastructure that supports revenue and cashflow. This is something that exists in nearly every other industry," said Tejpaul Bhatia, CEO of Nebex. "Support from these organizations gives Nebex the additional leverage and financial infrastructure to build the global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom